Drug Type CAR-T |
Synonyms CLDN18.2/TGF-β bispecific CAR-T cells(ImmPAC) |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), TGF-β stimulants(Transforming growth factor beta stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ImmPACT Bio USA, Inc.Startup |
Active Organization ImmPACT Bio USA, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stomach Cancer | Preclinical | US | ImmPACT Bio USA, Inc.Startup | 08 May 2024 |
CLDN18.2 positive Stomach Cancer | Discovery | US | ImmPACT Bio USA, Inc.Startup | 07 May 2024 |